Irving, Texas- based personalized cancer treatment purveyor Caris Life Sciences® has made a major impact at this week’s 2014 Gastrointestinal Cancers Symposium in San Francisco, California. BioNews Texas columnist Maureen Newman today filed a report on how the company is presenting on the implications of its novel Caris Molecular Intelligence™ technology, which continues to be regarded as a leading cancer profiling service on the market since its launch in 2006.
In addition, in a recent press release, Caris has also announced that it is taking part in a large international tumor profiling study of colorectal cancer (CRC), the results of which could provide groundbreaking, new insights in how to more effectively treat and eventually cure the disease. Caris Molecular Intelligence™ is being utilized to profile more than 7,000 colorectal cancer patients, which constitutes the largest, multi-national analysis in a single laboratory setting of the main molecular anomalies in colorectal cancer. Considering that colorectal cancer is now the third most common cancer worldwide, with metastatic disease accounting for 40 to 50 percent of newly diagnosed patients, the need for effective diagnostics and treatment for the disease is ever-increasing.
Read recent news about Caris Life Sciences:
[feed url=”http://bionews-tx.com/news/news-tags/caris-life-sciences/feed” number=”3″ ]
Fadi Braiteh, M.D., the co-author on the study, commented that, “This comprehensive analysis of more than 7,000 patient cases illustrates that treatment of this cancer as one single disease is a flawed approach. The variety of mutations identified also point the way to new combinations of therapies and protein targets that can help direct future treatments,” and adding that, “We are definitely moving from treating colon cancer as one disease to treating it as 20 to 30 different diseases. This research also highlights the feasibility of tumor profiling for colorectal cancer in the community setting, as well as establishes a high bar for standard of care for these patients.”
Researchers conducted the colorectal cancer study by evaluating “protein and DNA alterations in the EGFR pathway, including analysis of KRAS, NRAS, HRAS, BRAF, PIK3CA, ERBB4 and HER2 mutations/amplifications, as well as PTEN loss of expression and mutation in KRAS wild-type colorectal cancer patients,” according to the company’s press release. “This dataset highlights the importance of the EGFR pathway in treating this disease by identifying a high frequency of specific and co-incident pathway alterations that have therapeutic implications.”
Caris Life Sciences presenting author Gargi Basu, Ph.D. was able to draw some key conclusions from the study, which could dramatically impact prostate cancer treatment options in the future: “EGFR targeting therapies, cetuximab and panitumumab, are effective treatment for KRAS wild type CRC. Although mutations in KRAS predict resistance to EGFR Mab therapy, only 80 percent of CRC patients with KRAS wild type status respond to treatment. Testing for additional molecular alterations utilizing a multi-platform approach is critical to identifying those patients that are not likely to respond to anti-EGFR therapy alone and may respond better to a combination of targeted agents.”